The Bydureon BCise once-weekly injection has received FDA approval for use in children and teens age 10-17 after trial results showed it significantly reduced blood sugar in adolescents. This is the first once-weekly dose of the GLP-1 receptor agonist drug class approved for older children. Read more
Intensive treatment to achieve lower blood glucose levels is usually beneficial and recommended to help patients avoid long-term complications of diabetes. However, older adults have a higher risk of hypoglycemia than younger patients when given intensive treatment for glycemic control, so guidelines recommend they receive less aggressive glycemic targets. But there is evidence many older […]
Early research results for an injectable formulation combining prandial (pre-meal) insulin with pramlintide showed the combination improves blood glucose control and helps achieve weight loss in people with type 1 diabetes. Pramlintide is an analog of a hormone called amylin, which helps reduce blood sugar spikes after eating a meal. Read more
Adding the diabetes drug sotagliflozin (Zynquista) early in treatment of patients with type 2 diabetes was effective in reducing heart failure, heart attack, and stroke in the patients studied, according to trial results presented at the American Diabetes Association symposium. Read more
GLP-1 RAs are a class of diabetes medication that includes drugs like Trulicity, Ozempic, and Byetta. Drugs in this class have been shown to have a beneficial effect on heart health. Researchers examined whether GLP-1 RAs’ effectiveness in reducing blood glucose (HbA1c) levels is responsible for the reduction in cardiovascular risk associated with the medications. […]
A popular drug type, proton pump inhibitors (PPIs), that is used to treat heartburn and stomach ulcers has been found to improve blood sugar control in patients with diabetes when used in addition to their usual treatment. These drugs do not prevent diabetes in people who do not already have the condition, the researchers say. […]
The US Food and Drug Administration (FDA) recently approved a 2.4 mg/week subcutaneous dose of the GLP-1 receptor agonist semaglutide for weight loss in people who have obesity, or overweight with a related health complication. Semaglutide is already in use to treat type 2 diabetes, but the approval for this drug, to be sold under […]
A study found that the development of type 2 diabetes was reduced by 32% in participants who took the SGLT-2 inhibitor medication dapagliflozin instead of placebo, suggesting there may be a possible prevention, as well as treatment, role for this diabetes drug. Read more
Treatment-resistant bipolar depression may respond to the diabetes drug metformin, researchers say. A recent trial found that metformin treatment reversed insulin resistance in 50% of patients, which was associated with an improvement of the patients’ bipolar depressive symptoms. Read more
Pharma company Eli Lilly recently announced results of clinical trials for their new diabetes drug, Tirzepatide. The drug acts by mimicking the functions of incretin hormones, and would be a new type of medication to treat type 2 diabetes. It shows promise for improving blood glucose levels and helping achieve weight reduction. Read more
Researchers say a drug combination that can contribute to weight management, cagrilintide and semaglutide, has shown effectiveness in bodyweight reduction, even without lifestyle, diet, physical activity changes or surgery. Read more
Provention Bio has announced that the FDA’s advisory committee voted 10-7 that the benefits outweigh the risks of their drug candidate teplizumab, which is designed to delay the development of type 1 diabetes. The committee based its decision on safety and efficacy data from TN-10 Study in which a single 14-day course of teplizumab delayed […]
TTP399 is a potential new oral medication to lower and stabilize blood glucose in people with type 1 diabetes (T1D). If approved, TTP399 will be the first oral pill to treat T1D. In conjunction with insulin TTP399 should lower blood glucose without raising the risk of either diabetic ketoacidosis (DKA) or low blood glucose. Diabetes […]
Many patients with chronic kidney disease are at a higher risk for severe kidney and heart health issues. The DAPA-CKD trial was designed to see the impact of Dapagliflozin Propanediol, which is sold under the brand name Farxiga, in patients with and without type 2 diabetes who had chronic kidney disease. Read more
A recent study says that the access of people with type 2 diabetes to sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment has significant ethnic, gender and socioeconomic disparities, with women, Black or Asian patients less likely to receive SGLT-2 inhibitor treatment. Read more
The widely used type 2 diabetes drug metformin is often associated with lactic acidosis, especially in patients with kidney disease. However, a new study suggests this may not the case for patients with mild to moderate kidney disease. Read more
A study of the diabetes drug canagliflozin (Invokana) found that it was able to steadily reduce the risk of death and hospitalizations due to heart failure in patients with both type 2 diabetes and chronic kidney disease. Read more
The U.S. Food and Drug Administration (FDA) grants its Breakthrough Therapy designation to new drugs that show promise, to speed up the drugs’ development and review. A new type 1 diabetes drug, vTv Therapeutics’ TTP399, which is being developed as an adjunctive therapy to insulin for type 1 diabetes, has been granted this designation. Read […]
A recently published expert overview examines the cardiovascular benefits and risks of common diabetes drugs currently available in the United States, and lists which newer drug classes are beneficial for diabetes patients who already have indications of heart or blood vessel disease. Read more
SGLT-2 inhibitors, a diabetes drug class that includes drugs like canagliflozin (Invokana) have been shown to be beneficial for patients who have both type 2 diabetes and chronic kidney disease in regards to developing anemia. Read more
